Prescient Therapeutics Ltd

PTX

Company Profile

  • Business description

    Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

  • Contact

    Level 4, 100 Albert Road
    South Melbourne
    MelbourneVIC3205
    AUS

    T: +61 396927222

    https://www.ptxtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    1

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,998.103.30-0.04%
CAC 407,850.43106.021.37%
DAX 4024,240.82198.920.83%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,061.4937.680.42%
HKSE25,584.7646.690.18%
NASDAQ21,020.02127.330.61%
Nikkei 22541,988.18816.861.98%
NZX 50 Index12,829.2135.150.27%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,731.905.30-0.06%
SSE Composite Index3,589.026.730.19%

Market Movers